1. Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer

4. Educational Objectives

5. Lung Cancer Incidence and Pathology

6. Case 1: Introduction

7. Initial Work-Up for a Patient With Newly Diagnosed Advanced NSCLC

8. Guidelines for Molecular Testing in Advanced NSCLC

9. Plasma-Based Molecular Testing

10. Case 1 (cont)

11. First-Line Treatment Options for EGFR-Mutated Advanced NSCLC

12. LUX-Lung 3 and LUX-Lung 6 Patients With del19 EGFR-Mutated NSCLC

13. LUX-Lung 7: Head-to-Head Trial Gefitinib vs Afatinib in Treatment-Naive Patients With EGFR-Mutated NSCLC

14. ALK Rearrangement

15. ALK-Targeting Therapies

16. J-ALEX: Phase 3 Trial of Alectinib in Front-Line Treatment of ALK+ NSCLC

17. Case 1 (cont)

18. Common EGFR TKI Therapy Adverse Events

19. Management of EGFR TKI Adverse Events

20. Management of EGFR TKI Adverse Events (cont)

21. ALK Inhibitor Adverse Events and Management

22. Case 2: Progression on First-Line EGFR TKI

23. Osimertinib: Efficacy and Safety

24. Summary and Concluding Remarks

25. Abbreviations

26. Abbreviations (cont)